Litcius/Paper detail

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

Eugenio Mercuri, Nicolas Deconinck, Elena Mazzone, A. Nascimento, Maryam Oskoui, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Odile Boespflug‐Tanguy, Nathalie Goemans, Janbernd Kirschner, Anna Kostera‐Pruszczyk, Laurent Servais, Marianne Gerber, Ksenija Gorni, Omar Khwaja, Heidemarie Kletzl, R. Scalco, Hannah Staunton, Wai Yin Yeung, Carmen Martin, Paulo Fontoura, John W Day, Joseph J. Volpe, John Posner, Ulrich Kellner, Rosaline C. M. Quinlivan, Aurore Daron, Stéphanie Delstanche, Romain Bruninx, Fabian Dal Farra, O. Schneider, Nicolas Deconinck, Irina Balikova, Patricia Delbeke, Inge Joniau, Valentine Tahon, Sylvia Wittevrongel, Elke De Vos, Nathalie Goemans, Ingele Casteels, Liesbeth De Waele, Irina Balikova, Cathérine Cassiman, Lies Prové, David Kinoo, Lisa Vancampenhout, M. van den Hauwe, Annelies Van Impe, Alexandra Prufer de Queiroz Campos Araújo, Aline Chacon Pereira, Flávia Nardes, Lorena Haefeli, Júlia Dutra Rossetto, Marcos Ferreira Rebel, Jaqueline Almeida Pereira, Craig Campbell, Sapna Sharan, Wendy L. McDonald, Cheryl Scholtes, Jean K. Mah, Maria Sframeli, Angela W. Chiu, Jane Hagel, Maryam Oskoui, Raquel Beneish, Gaela Cariou-Palmer, Connie Pham, Daniela Toffoli, Stéphanie Arpin, Sarah Turgeon Desilets, Yi Wang, Chaoping Hu, Jianfeng Huan, Qian Chen, Li Shen, Ying Xiao, Zhenxuan Zhou, Hui Li, Sujuan Wang, Hui Xiong, Xingzhi Chang, Hui Dong, Ying Liu, Tian Sang, Cuijie Wei, Jing Wen, Yiwen Cao, Xingyao Ly, Jing Wen, Jingjing Zhao, Wenzhu Li, Lun Qin, Nina Barišić, Martina Galiot Delić, Petra Kristina Ivkić, Nenad Vukojević, Ivana Kern, B Najdanović, Marin Skugor

2021The Lancet Neurology216 citationsDOI

Topics & Concepts

MedicineSpinal muscular atrophyPlaceboClinical endpointPhysical therapyAtrophyClinical trialAdverse effectInternal medicineDiseasePathologyAlternative medicineNeurogenetic and Muscular Disorders ResearchAmyotrophic Lateral Sclerosis ResearchCardiomyopathy and Myosin Studies
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial | Litcius